AbbVie Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Michael
- Full Time Employees
- 57,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. (NYSE: ABBV) is a global research-based biopharmaceutical company that discovers, develops, manufactures and commercializes innovative medicines across immunology, oncology, neuroscience, eye care, aesthetics, virology and gastroenterology. Founded in 2013 as a spin-off from Abbott Laboratories and headquartered in North Chicago, Illinois, the company operates in more than 70 countries with approximately 55,000 employees worldwide. Its core products include Humira (adalimumab) for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease and ulcerative colitis; Skyrizi (risankizumab) and Rinvoq (upadacitinib), both interleukin inhibitors for immunology indications; Imbruvica (ibrutinib) and Venclexta (venetoclax) for oncology; Vraylar (cariprazine) for schizophrenia and bipolar disorder; Botox for aesthetics; Mavyret (glecaprevir/pibrentasvir) for hepatitis C; and Epkinly (epcoritamab) for blood cancers, among others including Duopa/Duodopa, Ubrelvy and Vyalev in neuroscience and pipeline candidates for Parkinson's disease. AbbVie markets its portfolio to patients, healthcare providers and health systems globally, with major revenue contributions from the United States and international markets. In recent developments, the company completed acquisitions of ImmunoGen for $10.1 billion in 2024 to bolster ovarian cancer treatments with Elahere, Cerevel Therapeutics for $8.7 billion to expand neuroscience, Aliada Therapeutics for $1.4 billion, Nimble Therapeutics and Capstan Therapeutics in 2024-2025 for immunology enhancements, and Gilgamesh Pharmaceuticals in 2025 for a psychiatry drug bretisilocin valued up to $1.2 billion; it also announced partnerships such as $1.64 billion with Neomorph for molecular glue degraders and licensing from Gubra for obesity treatments, alongside over 30 deals since 2024 and manufacturing expansions including a $195 million API facility and $70 million biologics site in the U.S. to support over $10 billion in domestic investments.
For Global Pharma Exposure Is the VanEck Pharmaceutical ETF or iShares Healthcare Fund the Better Buy in 2026?
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
Dimensional Fund Advisors LP Sells 868,264 Shares of AbbVie Inc. $ABBV
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
3 Biggest Pharma Giants: Buy, Sell or Hold?
AIA Group Ltd Has $16.22 Million Stock Position in AbbVie Inc. $ABBV
AbbVie Inc. $ABBV Position Increased by Allspring Global Investments Holdings LLC
Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?
Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?
SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty
AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100